Reportlinker Adds World Analgesics Market Report

NEW YORK--(Business Wire)--
Reportlinker.com announces that a new market research report is available in its
catalogue.

World Analgesics Market

http://www.reportlinker.com/p098419/World-Analgesics-Market.html

This report analyzes the worldwide markets for Analgesics in Millions of US$.
The major product segments analyzed are Internal Analgesics, (Aspirin,
Acetaminophen, Ibuprofen, and Others (includes combination drugs)) and External
Analgesics. The report provides separate comprehensive analytics for the US,
Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual
forecasts are provided for each region for the period of 2001 through 2015. A
ten-year historic analysis is also provided for these markets with annual market
analytics. The report profiles 139 companies including many key and niche
players worldwide such as Bayer Consumer Care, Bristol-Myers Squibb Co., Johnson
& Johnson, McNeil Consumer Healthcare, Novartis International AG, Pfizer, Inc.,
Reckitt Benckiser Group Plc, W. F. Young, Inc., Wyeth, and Wyeth Consumer
Healthcare. Market data and analytics are derived from primary and secondary
research. Company profiles are mostly extracted from URL research and reported
select online sources.

ANALGESICS MCP-5064 A GLOBAL STRATEGIC BUSINESS REPORT

CONTENTS

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1 Disclaimers I-2 Data
Interpretation & Reporting Level I-2 Quantitative Techniques & Analytics I-3
Product Definitions and Scope of Study I-3 1. Internal Analgesics I-3 Aspirin
I-3 Acetaminophen I-3 Ibuprofen I-4 Others I-4 2. External Analgesics I-4

II. EXECUTIVE SUMMARY

1. Global Analgesics Market Overview II-1 Pain Therapeutic Market II-1
Analgesics Market - Offering Immense Potential II-1 Internal Analgesics - Riding
on a Crest II-1 Liquid Analgesics Register Rapid Growth II-2 Neuropathic Pain-
Unexplored II-2 Ibuprofen Scoring High II-2 External Analgesics - In a slump
II-2 Boom in Demand for Topical Analgesic Patches II-3

2. Product Overview II-4 A Brief History II-4 Analgesics II-4 Definition II-4
Types of Pain II-4 Acute Pain II-4 Chronic Pain II-5 Drugs Combating Pain II-5
Local Anesthetics II-5 Narcotic Opioids II-5 Nonsteroidal Anti-Inflammatory
Drugs (NSAIDs) II-6 Types of NSAIDS II-6 Common NSAIDs II-7 Clinical Use... II-7
Side Effects... II-8 Aspirin II-8 The Wonder Drug... II-8 PolyAspirin: The Safer
and More Potent Polymer Variant of Aspirin II-9 Mode of Action II-9
Contraindications II-9 Acetaminophen II-9 Acetaminophen Protects Heart Muscle
II-10 Acetaminophen Reduces Incidence of Ovarian Cancer II-10 Ibuprofen,
Ketoprofen and Naproxen II-10 Combination Analgesics II-10

Table 1: Opioid Analgesics Market: Percentage Share of Opioid / Acetaminophen
Combination Products in the Opioid Script Volume (includes corresponding
Graph/Chart) II-11 OTC Analgesics: An Overview II-11

3. Industry Dynamics II-12 Escalating R&D Costs: A Boon or Bane? II-12 Timeline
of the Drug Approval Process II-12 Cox II Crisis Tarnishes Industry Growth II-12
Novel Therapies to Propel Opioid and Non-Opioid Therapies II-13 Rx-to-OTC Switch
II-13 Why Consumers Prefer OTC Drugs? II-13 Development of Analgesic Tripeptides
II-13

4. Recent Clinical Trials II-14 PLx Initiates Clinical Trial For Aspirin-PC
II-14 Neurodiscovery Receives Approval for NSL-101 Phase II Clinical Trials
II-14

5. Product Innovations/Introductions II-15 ProEthic Pharmaceuticals Releases
Ibudone for Acute Pain Management II-15 Dr. Reddy`s Laboratories Introduces
Supanac for Acute Pain Management II-15 Mallinckrodt Introduces Magnacet Tablets
for Pain Management II-15 Wockhardt to Launch New Painkiller II-15 Paladin Labs
and Labopharm Introduce Tridural II-15 Shionogi & Co Introduces OxiNorm Powder
0.5% II-15 McNeil Brings Chewable TYLENOL GoTabs Tablets II-16 Barr Unveils
Generic Version of ACTIQ II-16 Novartis Launches Voltarol Pain-Eze Emulgel .
II-16 TheraQuest Launches TQ-1017 II-16 Mentholatum Company Introduces WellPatch
Deep Heat Patch II-16 SSP and Mepha Launch Olfen Patch in Switzerland II-17 W.F.
Young Expands Absorbine Jr II-17 Pfizer Unveils Neurontin II-17 Ligand
Pharmaceuticals Introduces Avinza in the US II-17 AlphaRx Introduces Flexogan
II-17 Essere Introduces Roll-On Analgesic II-17 Novartis Introduces Topical
Analgesic and Cough Suppressant in Sticks II-17 SSL International Introduces
Easy-To-Swallow Version of Paramol II-18 Janssen Launches Duragesic, a Narcotic
Analgesic II-18 Abbott Laboratories Launches Narcotic Analgesic II-18
Ortho-McNeil Launches Flexeril II-18 Elkins-Sinn Launches Opioid Analgesic II-18
FH Faulding Launches Narcotic Analgesic, Kadian II-18 ICN Pharmaceuticals
Launches Opioid Aanalgesic, Levo Dromoran II-18 Amarin Launches Motofen, a
Narcotic Analgesic and Anti- Cholinergic II-18 Purdue Pharma Launches MS Contin,
a Narcotic Analgesic II-19 Able Laboratories Unveils New Versions of
Acetaminophen and Hydrocodone Bitartrate II-19 Whitehall Launches Anadin
Analgesic Tablets in South Africa II-19 Leiner Launches Ibuprofen Softgel
Capsules II-19 Crookes Healthcare Launches Ibuprofen Singles for Children II-19
SSL International Launches Cuprofen Ibuprofen for Children II-19 Lloydspharmacy
Launches Ibuprofen Suspension for Children II-19

6. Recent Industry Activity II-20 Bayer to Acquire Sagmel`s OTC Business II-20
E5 Pharma Receives Approval from FDA II-20 Pharmaceutical Associates Receives
Approval from FDA II-20 Concord Receives New Drug Approvals II-20 Hisamitsu
Receives Approval for SALONPAsÒ II-20 Johnson & Johnson Submits NDA to FDA II-20
Nycomed and Paladin Inks Joint-Promotion Agreement for Tridural II-20 Akela
Extends Agreement with Janssen II-21 Daiichi and Lead Chemical Receives Approval
for LoxoninÒ Tape II-21 Tokio Marine Capital to Acquire Showa Yakuhin Kako II-21
Corgenix Collaborates with Randox Laboratories II-21 Corgenix Receives EPO
Approval for Aspirin Resistance Method II-21 IOL to Expand Production Capacity
II-22 American Oriental Bioengineering Partners with China Aoxing II-22 Abraxis
Takes Over Shimoda and its Subsidiary Co. II-22 Ranbaxy Receives Approval from
FDA II-22 Wockhardt Receives FDA Approval for DPN + APAP II-22 Alpharma to
Market Flector Patch in the US II-22 Auriga and Mikart Inks Agreement to Market
Codein II-22 Watson Receives FDA Approval for Oxycodone Hydrochloride and
Ibuprofen II-23 Labopharm`s Tramadol Receives Approval in Canada II-23 Lion
Acquires BUFFERIN Trademark Rights II-23 Grunenthal`s Extends Licensing
Agreement with Ortho-McNeil II-23 China Aoxing Pockets LRT II-23 Anesiva Inks
Joint Venture Agreement Wanbang II-23 Beijing Med-Pharm Inks Agreement with
Lotus Healthcare II-24 LAB International Inks Licensing Agreement with Janssen
Pharmaceutica II-24 Three Sixty Pockets Rockford-Montgomery Labs II-24 Antares
Enters into License and Development Agreement for Opioid Analgesic II-24 Abraxis
BioScience Acquires AstraZeneca`s Analgesic Brand Portfolio II-24
IntelliPharmaCeutics Inks Agreement with Larasan II-24 Ranbaxy and Ethypharm Ink
In-licensing Agreement II-25 Elite Collaborates with TPN to Co-develop Analgesic
Drug II-25 Novartis Acquires Hexal Company and Major Stake in Eon Labs . II-25
NovaDel Pharma Receives Patent for Buccal Sprays Technology II-25 Auxilium
Pharmaceuticals Enters into a Licensing Agreement with PharmaForm II-25 EC
Sanctions Sale of Elan`s Prialt II-26 EpiCept Corp. Merges with Maxim
Pharmaceuticals, Inc II-26 Reckitt Benckiser plc Acquires Boots Healthcare
International II-26 Bayer Acquires Non-prescription Drug Business of Roche II-26
Bextra (Valdecoxib) Receives Green Signal from Health Canada II-27 Rhodia
Announces Closure of Acetaminophen Plant in Louisiana II-27 NicOx Re-Gains
Rights to CINOD from AstraZeneca II-27

7. Focus on Select Key Players II-28 Bayer Consumer Care (USA) II-28
Bristol-Myers Squibb Company (USA) II-28 Johnson & Johnson (USA) II-28 McNeil
Consumer Healthcare (Canada) II-28 Novartis International AG (Switzerland) II-29
Pfizer Inc. (USA) II-29 Reckitt Benckiser Group Plc (UK) II-29 W. F. Young Inc
(USA) II-29 Wyeth (USA) II-30 Wyeth Consumer Healthcare II-30

8. Global Market Perspective II-31

Table 2: World Recent Past, Current & Future Analysis for Analgesics by
Geographic Region/Country - US, Canada, Japan, Europe, Asia-Pacific (excluding
Japan), Latin America and Rest of World Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes
corresponding Graph/Chart) II-31

Table 3: World Long-term Projections for Analgesics by Geographic Region/Country
- US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and
Rest of World Markets Independently Analyzed with Annual Sales Figures in US$
Million for Years 2011 through 2015 (includes corresponding Graph/Chart) II-32

Table 4: World Historic Review for Analgesics by Geographic Region/Country - US,
Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of
World Markets Independently Analyzed with Annual Sales Figures in US$ Million
for Years 1991 through 2000 (includes corresponding Graph/Chart) II-33

Table 5: World 15-Year Perspective for Analgesics by Geographic Region/Country -
Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), Latin America and Rest of World Markets for Years 1998, 2008
& 2012 (includes corresponding Graph/Chart) II-34

Table 6: World Recent Past, Current & Future Analysis for Internal Analgesics by
Geographic Region/ Country - US, Canada, Japan, Europe, Asia-Pacific (excluding
Japan), Latin America and Rest of World Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes
corresponding Graph/Chart) II-35

Table 7: World Long-term Projections for Internal Analgesics by Geographic
Region / Country - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),
Latin America and Rest of World Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2011 through 2015 (includes corresponding
Graph/Chart) II-36

Table 8: World Historic Review for Internal Analgesics by Geographic
Region/Country - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),
Latin America and Rest of World Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 1991 through 2000 (includes corresponding
Graph/Chart) II-37

Table 9: World 15-Year Perspective for Internal Analgesics by Geographic
Region/Country - Percentage Breakdown of Dollar Sales for US, Canada, Japan,
Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets
for Years 1998, 2008 & 2012 (includes corresponding Graph/Chart) II-38

Table 10: World Recent Past, Current & Future Analysis for Internal Analgesics
by Product Segment - Aspirin, Acetaminophen, Ibuprofen, and Others Markets
Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001
through 2010 (includes corresponding Graph/Chart) II-39

Table 11: World Long-term Projections for Internal Analgesics by Product Segment
- Aspirin, Acetaminophen, Ibuprofen, and Others Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart) II-39

Table 12: World Historic Review for Internal Analgesics by Product Segment -
Aspirin, Acetaminophen, Ibuprofen, and Others Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 1991 through 2000 (includes
corresponding Graph/Chart) II-40

Table 13: World 15-Year Perspective for Internal Analgesics by Product Segment -
Percentage Breakdown of Dollar Sales for Aspirin, Acetaminophen, Ibuprofen, and
Others Markets for Years 1998, 2008 & 2012 (includes corresponding Graph/Chart)
II-40

Table 14: World Recent Past, Current & Future Analysis for Aspirin by Geographic
Region/Country - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),
Latin America and Rest of World Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2001 through 2010 (includes corresponding
Graph/Chart) II-41

Table 15: World Long-term Projections for Aspirin by Geographic Region/Country -
US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and
Rest of World Markets Independently Analyzed with Annual Sales Figures in US$
Million for Years 2011 through 2015 (includes corresponding Graph/Chart) II-42

Table 16: World Historic Review for Aspirin by Geographic Region/Country - US,
Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of
World Markets Independently Analyzed with Annual Sales Figures in US$ Million
for Years 1991 through 2000 (includes corresponding Graph/Chart) II-43

Table 17: World 15-Year Perspective for Aspirin by Geographic Region/Country -
Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), Latin America and Rest of World Markets for Years 1998, 2008
& 2012 (includes corresponding Graph/Chart) II-44

Table 18: World Recent Past, Current & Future Analysis for Acetaminophen by
Geographic Region/ Country - US, Canada, Japan, Europe, Asia-Pacific (excluding
Japan), Latin America and Rest of World Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes
corresponding Graph/Chart) II-45

Table 19: World Long-term Projections for Acetaminophen by Geographic
Region/Country - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),
Latin America and Rest of World Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2011 through 2015 (includes corresponding
Graph/Chart) II-46

Table 20: World Historic Review for Acetaminophen by Geographic Region/Country -
US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and
Rest of World Markets Independently Analyzed with Annual Sales Figures in US$
Million for Years 1991 through 2000 (includes corresponding Graph/Chart) II-47

Table 21: World 15-Year Perspective for Acetaminophen by Geographic
Region/Country - Percentage Breakdown of Dollar Sales for US, Canada, Japan,
Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets
for Years 1998, 2008 & 2012 (includes corresponding Graph/Chart) II-48

Table 22: World Recent Past, Current & Future Analysis for Ibuprofen by
Geographic Region/Country - US, Canada, Japan, Europe, Asia-Pacific (excluding
Japan), Latin America and Rest of World Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes
corresponding Graph/Chart) II-49

Table 23: World Long-term Projections for Ibuprofen by Geographic Region/Country
- US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and
Rest of World Markets Independently Analyzed with Annual Sales Figures in US$
Million for Years 2011 through 2015 (includes corresponding Graph/Chart) II-50

Table 24: World Historic Review for Ibuprofen by Geographic Region/Country - US,
Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of
World Markets Independently Analyzed with Annual Sales Figures in US$ Million
for Years 1991 through 2000 (includes corresponding Graph/Chart) II-51

Table 25: World 15-Year Perspective for Ibuprofen by Geographic Region/Country -
Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), Latin America and Rest of World Markets for Years 1998, 2008
& 2012 (includes corresponding Graph/Chart) II-52

Table 26: World Recent Past, Current & Future Analysis for *Other Internal
Analgesics by Geographic Region/Country - US, Canada, Japan, Europe,
Asia-Pacific (excluding Japan), Latin America and Rest of World Markets
Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001
through 2010 (includes corresponding Graph/Chart) II-53

Table 27: World Long-term Projections for *Other Internal Analgesics by
Geographic Region/Country - US, Canada, Japan, Europe, Asia-Pacific (excluding
Japan), Latin America and Rest of World Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart) II-54

Table 28: World Historic Review for *Other Internal Analgesics by Geographic
Region / Country - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),
Latin America and Rest of World Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 1991 through 2000 (includes corresponding
Graph/Chart) II-55

Table 29: World 15-Year Perspective for *Other Internal Analgesics by Geographic
Region/Country - Percentage Breakdown of Dollar Sales for US, Canada, Japan,
Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets
for Years 1998, 2008 & 2012 (includes corresponding Graph/Chart) II-56

Table 30: World Recent Past, Current & Future Analysis for External Analgesics
by Geographic Region/ Country - US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), Latin America and Rest of World Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years 2001 2010 (includes
corresponding Graph/Chart) II-57

Table 31: World Long-term Projections for External Analgesics by Geographic
Region / Country - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),
Latin America and Rest of World Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2011 through 2015 (includes corresponding
Graph/Chart) II-58

Table 32: World Historic Review for External Analgesics by Geographic
Region/Country - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),
Latin America and Rest of World Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 1991 2000 (includes corresponding Graph/Chart)
II-59

Table 33: World 15-Year Perspective for External Analgesics by Geographic Region
/Country - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe,
Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for
Years 1998, 2008 & 2012 (includes corresponding Graph/Chart) II-60

III-A. MARKET

1. The United States III-1 A.Market Analysis III-1 Current and Future Analysis
III-1 Pain Statistics in the US III-1 Industry Overview III-1 Internal
Analgesics III-2 Cox-2 Drugs in for Some Trouble III-2 Switch to OTC Drugs III-2

Table 34: US Internal Tablet Analgesics Market (2007): Percentage Share
Breakdown of Leading Ten Brands by Revenues (includes corresponding Graph/Chart)
III-2

Table 35: US Internal Liquid Analgesics Market (2007): Percentage Share
Breakdown of Leading Ten Brands by Revenues (includes corresponding Graph/Chart)
III-3

Table 36: Internal Analgesics Market in the U.S. By Retail Channel (2008E):
Percentage Share by Value Sales for Discount Stores, Food / Drug Combination
Stores, Chain Drug Stores, Supermarkets, and Independent Drug Stores (includes
corresponding Graph/Chart) III-3 Promotional Strategies for the Internal
Analgesics III-3

Table 37: Market for Internal Liquid Analgesics in the U.S. by Retail Channel
(2008E): Percentage Share by Value Sales for Supermarkets, Drug Stores, and
Discounters (includes corresponding Graph/Chart) III-3 Pediatric Analgesics: The
New Kid on the Block III-4 External Analgesics III-4 Stretching Boundaries III-4

Table 38: US External Analgesics Market (2007): Percentage Share Breakdown of
Leading Ten Brands by Revenues (includes corresponding Graph/Chart) III-4

Table 39: External Analgesics Market in the U.S. By Retail Channel (2008E):
Percentage Share by Value Sales for Chain drug stores, Discount stores,
Food/drug combination stores, Independent drug stores, and Supermarkets
(includes corresponding Graph/Chart) III-4 Rubs, Patches: Driving the External
Analgesics Market III-4 Patch Relief Gaining Momentum III-5 Product
Innovations/Introductions III-5 Strategic Corporate Developments III-6 Major
Players III-9 B.Market Analytics III-11

Table 40: US Recent Past, Current & Future Analysis for Analgesics by Product
Segment - Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and
External Analgesics Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart)
III-11

Table 41: US Long-term Projections for Analgesics by Product Segment - Internal
Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External
Analgesics Markets Independently Analyzed with Annual Sales Figures in US$
Million for Years 2011 through 2015 (includes corresponding Graph/Chart) III-12

Table 42: US Historic Review for Analgesics by Product Segment - Internal
Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External
Analgesics Markets Independently Analyzed with Annual Sales Figures in US$
Million for Years 1991 through 2000 (includes corresponding Graph/Chart) III-12

Table 43: US 15-Year Perspective for Analgesics by Product Segment - Percentage
Breakdown of Dollar Sales for Internal Analgesics (Aspirin, Acetaminophen,
Ibuprofen and Others) and External Analgesics Markets for 1998, 2008 & 2012
(includes corresponding Graph/Chart) III-13

2. Canada III-14 A.Market Analysis III-14 Current and Future Analysis III-14 Key
Players III-14 McNeil Consumer Healthcare III-14 Product Launches III-14
Strategic Corporate Developments III-14 B.Market Analytics III-16

Table 44: Canadian Recent Past, Current & Future Analysis for Analgesics by
Product Segment - Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and
Others) and External Analgesics Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2001 through 2010 (includes corresponding
Graph/Chart) III-16

Table 45: Canadian Long-term Projections for Analgesics by Product Segment -
Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External
Analgesics Markets Independently Analyzed with Annual Sales Figures in US$
Million for Years 2011 through 2015 (includes corresponding Graph/Chart) III-17

Table 46: Canadian Historic Review for Analgesics by Product Segment - Internal
Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External
Analgesics Markets Independently Analyzed with Annual Sales Figures in US$
Million for Years 1991 through 2000 (includes corresponding Graph/Chart) III-17

Table 47: Canadian 15-Year Perspective for Analgesics by Product Segment -
Percentage Breakdown of Dollar Sales for Internal Analgesics (Aspirin,
Acetaminophen, Ibuprofen and Others) and External Analgesics Markets for 1998,
2008 & 2012 (includes corresponding Graph/Chart) III-18

3. Japan III-19 A.Market Analysis III-19 Current and Future Analysis III-19
Competitive Scenario III-19

Table 48: OTC Analgesics Market in Japan (2005): Market Share of Leading Players
by Value - Lion, Arax, Taisho Pharmaceutical, SS Pharmaceutical, Shionogi, and
Others (includes corresponding Graph/Chart) III-19 Strategic Corporate
Developments III-19 B.Market Analytics III-21

Table 49: Japanese Recent Past, Current & Future Analysis for Analgesics by
Product Segment - Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and
Others) and External Analgesics Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2001 through 2010 (includes corresponding
Graph/Chart) III-21

Table 50: Japanese Long-term Projections for Analgesics by Product Segment -
Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External
Analgesics Markets Independently Analyzed with Annual Sales Figures in US$
Million for Years 2011 through 2015 (includes corresponding Graph/Chart) III-22

Table 51: Japanese Historic Review for Analgesics by Product Segment - Internal
Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External
Analgesics Markets Independently Analyzed with Annual Sales Figures in US$
Million for Years 1991 through 2000 (includes corresponding Graph/Chart) III-22

Table 52: Japanese 15-Year Perspective for Analgesics by Product Segment -
Percentage Breakdown of Dollar Sales for Internal Analgesics (Aspirin,
Acetaminophen, Ibuprofen and Others) and External Analgesics Markets for 1998,
2008 & 2012 (includes corresponding Graph/Chart) III-23

4. Europe III-24 A.Market Analysis III-24 Current and Future Analysis III-24 By
Product Group/Segment III-24 European Pain Management Market III-24 Generics
Restrain Revenue Growth III-24

Table 53: Popular Brands of Pain & Inflammation Medication in Europe (2004):
Percentage Share of Aspirin, Voltaren, Ibuprofen, Nurofen, Vioxx, Celebre,
Tylenol, Aulin, Anadin, and Paracetamol (includes corresponding Graph/Chart)
III-25 B.Market Analytics III-26

Table 54: European Recent Past, Current & Future Analysis for Analgesics by
Geographic Region/Country - France, Germany, UK, Italy, Spain, Russia and Rest
of Europe Markets Independently Analyzed with Annual Sales Figures in US$
Million for Years 2001 through 2010 (includes corresponding Graph/Chart) III-26

Table 55: European Long-term Projections for Analgesics by Geographic
Region/Country - France, Germany, UK, Italy, Spain, Russia and Rest of Europe
Markets Independently Analyzed with Annual Sales Figures in US$ Million for
Years 2011 through 2015 (includes corresponding Graph/Chart) III-26

Table 56: European Recent Past, Current & Future Analysis for Analgesics by
Product Segment - Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and
Others) and External Analgesics Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2001 through 2010 (includes corresponding
Graph/Chart) III-27

Table 57: European Long-term Projections for Analgesics by Product Segment -
Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External
Analgesics Markets Independently Analyzed with Annual Sales Figures in US$
Million for Years 2011 through 2015 (includes corresponding Graph/Chart) III-27

Table 58: European Historic Review for Analgesics by Geographic Region/Country -
France, Germany, UK, Italy, Spain, Russia and Rest of Europe Markets
Independently Analyzed with Annual Sales Figures in US$ Million for Years 1991
through 2000 (includes corresponding Graph/Chart) III-28

Table 59: European Historic Review for Analgesics by Product Segment - Internal
Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External
Analgesics Markets Independently Analyzed with Annual Sales Figures in US$
Million for Years 1991 through 2000 (includes corresponding Graph/Chart) III-28

Table 60: European 15-Year Perspective for Analgesics by Geographic
Region/Country - Percentage Breakdown of Dollar Sales for France, Germany, UK,
Italy, Spain, Russia and Rest of Europe Markets for Years 1998, 2008 & 2012
(includes corresponding Graph/Chart) III-29

Table 61: European 15-Year Perspective for Analgesics by Product Segment -
Percentage Breakdown of Dollar Sales for Internal Analgesics (Aspirin,
Acetaminophen, Ibuprofen and Others) and External Analgesics Markets for Years
1998, 2008 & 2012 (includes corresponding Graph/Chart) III-30

4a. France III-31 A.Market Analysis III-31 Current and Future Analysis III-31
Competitive Scenario III-31

Table 62: Analgesics Market in France (2005): Market Share of Leading Players by
Value - Bristol-Myers Squibb, Therapix, Roche, Bayer Group, Wyeth Consumer
Healthcare, and Others) (includes corresponding Graph/Chart) III-31 Key Player
III-31 Sanofi Aventis III-31 B.Market Analytics III-32

Table 63: French Recent Past, Current & Future Analysis for Analgesics by
Product Segment - Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and
Others) and External Analgesics Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2001 through 2010 (includes corresponding
Graph/Chart) III-32

Table 64: French Long-term Projections for Analgesics by Product Segment -
Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External
Analgesics Markets Independently Analyzed with Annual Sales Figures in US$
Million for Years 2011 through 2015(includes corresponding Graph/Chart) III-33

Table 65: French Historic Review for Analgesics by Product Segment - Internal
Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External
Analgesics Markets Independently Analyzed with Annual Sales Figures in US$
Million for Years 1991 through 2000 (includes corresponding Graph/Chart) III-33

Table 66: French 15-Year Perspective for Analgesics by Product Segment -
Percentage Breakdown of Dollar Sales for Internal Analgesics (Aspirin,
Acetaminophen, Ibuprofen and Others) and External Analgesics Markets for 1998,
2008 & 2012 (includes corresponding Graph/Chart) III-34

4b. Germany III-35 A.Market Analysis III-35 Current and Future Analysis III-35
Competitive Scenario III-35

Table 67: Analgesics Market in Germany (2005): Market Share of Leading Players
by Value - Bayer Group, Boehringer Ingelheim, Wyeth Consumer Healthcare, and
Others (includes corresponding Graph/Chart) III-35 B.Market Analytics III-36

Table 68: German Recent Past, Current & Future Analysis for Analgesics by
Product Segment - Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and
Others) and External Analgesics Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2001 through 2010 (includes corresponding
Graph/Chart) III-36

Table 69: German Long-term Projections for Analgesics by Product Segment -
Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External
Analgesics Markets Independently Analyzed with Annual Sales Figures in US$
Million for Years 2011 through 2015 (includes corresponding Graph/Chart) III-37

Table 70: German Historic Review for Analgesics by Product Segment - Internal
Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External
Analgesics Markets Independently Analyzed with Annual Sales Figures in US$
Million for Years 1991 through 2000 (includes corresponding Graph/Chart) III-37

Table 71: German 15-Year Perspective for Analgesics by Product Segment -
Percentage Breakdown of Dollar Sales for Internal Analgesics (Aspirin,
Acetaminophen, Ibuprofen and Others) and External Analgesics Markets for 1998,
2008 & 2012 (includes corresponding Graph/Chart) III-38

4c. The United Kingdom III-39 A.Market Analysis III-39 Current and Future
Analysis III-39 Key Player III-39 Reckitt Benckiser Group Plc III-39 Competitive
Scenario III-39

Table 72: Analgesics Market in the United Kingdom (2005E): Market Shares of
Leading Players by Value - Boots Healthcare, GlaxoSmithKline, and Others
(includes corresponding Graph/Chart) III-39 Ten Leading Analgesics Brands for
Children in the UK Analgesics Market III-39 Strategic Corporate Developments
III-39 B.Market Analytics III-40

Table 73: UK Recent Past, Current & Future Analysis for Analgesics by Product
Segment - Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and
External Analgesics Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart)
III-40

Table 74: UK Long-term Projections for Analgesics by Product Segment - Internal
Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External
Analgesics Markets Independently Analyzed with Annual Sales Figures in US$
Million for Years 2011 through 2015(includes corresponding Graph/Chart) III-41

Table 75: UK Historic Review for Analgesics by Product Segment - Internal
Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External
Analgesics Markets Independently Analyzed with Annual Sales Figures in US$
Million for Years 1991 through 2000 (includes corresponding Graph/Chart) III-41

Table 76: UK 15-Year Perspective for Analgesics by Product Segment - Percentage
Breakdown of Dollar Sales for Internal Analgesics (Aspirin, Acetaminophen,
Ibuprofen and Others) and External Analgesics Markets for 1998, 2008 & 2012
(includes corresponding Graph/Chart) III-42

4d. Italy III-43 A.Market Analysis III-43 Current and Future Analysis III-43
Competitive Scenario III-43

Table 77: Analgesics Market in Italy (2005): Market Share of Leading Players by
Value - Bayer Group, Angelini, Novartis, Bristol-Myers Squibb, Boots Healthcare,
and Others (includes corresponding Graph/Chart) III-43 B.Market Analytics III-44

Table 78: Italian Recent Past, Current & Future Analysis for Analgesics by
Product Segment - Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and
Others) and External Analgesics Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2001 through 2010 (includes corresponding
Graph/Chart) III-44

Table 79: Italian Long-term Projections for Analgesics by Product Segment -
Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External
Analgesics Markets Independently Analyzed with Annual Sales Figures in US$
Million for Years 2011 through 2015 (includes corresponding Graph/Chart) III-45

Table 80: Italian Historic Review for Analgesics by Product Segment - Internal
Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External
Analgesics Markets Independently Analyzed with Annual Sales Figures in US$
Million for Years 1991 through 2000 (includes corresponding Graph/Chart) III-45

Table 81: Italian 15-Year Perspective for Analgesics by Product Segment -
Percentage Breakdown of Dollar Sales for Internal Analgesics (Aspirin,
Acetaminophen, Ibuprofen and Others) and External Analgesics Markets for 1998,
2008 & 2012 (includes corresponding Graph/Chart) III-46

4e. Spain III-47 A.Market Analysis III-47 Current and Future Analysis III-47
Competitive Scenario III-47

Table 82: Analgesics Market in Spain (2005): Market Share of Leading Players by
Value - Bayer Group, Boehringer Ingelheim, Bristol-Myers Squibb, Novartis, Boots
Healthcare, and Others (includes corresponding Graph/Chart) III-47 B.Market
Analytics III-48

Table 83: Spanish Recent Past, Current & Future Analysis for Analgesics by
Product Segment - Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and
Others) and External Analgesics Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2001 through 2010 (includes corresponding
Graph/Chart) III-48

Table 84: Spanish Long-term Projections for Analgesics by Product Segment -
Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External
Analgesics Markets Independently Analyzed with Annual Sales Figures in US$
Million for Years 2011 through 2015(includes corresponding Graph/Chart) III-49

Table 85: Spanish Historic Review for Analgesics by Product Segment - Internal
Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External
Analgesics Markets Independently Analyzed with Annual Sales Figures in US$
Million for Years 1991 through 2000 (includes corresponding Graph/Chart) III-49

Table 86: Spanish 15-Year Perspective for Analgesics by Product Segment -
Percentage Breakdown of Dollar Sales for Internal Analgesics (Aspirin,
Acetaminophen, Ibuprofen and Others) and External Analgesics Markets for 1998,
2008 & 2012 (includes corresponding Graph/Chart) III-50

4f. Rest of Europe III-51 A.Market Analysis III-51 Current and Future Analysis
III-51 Product Innovations/Introductions III-51 Strategic Corporate Developments
III-51 Key Player III-52 Novartis International AG (Switzerland) III-52 B.Market
Analytics III-53

Table 87: Rest of Europe Recent Past, Current & Future Analysis for Analgesics
by Product Segment - Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and
Others) and External Analgesics Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2001 through 2010 (includes corresponding
Graph/Chart) III-53

Table 88: Rest of Europe Long-term Projections for Analgesics by Product Segment
- Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and
External Analgesics Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
III-54

Table 89: Rest of Europe Historic Review for Analgesics by Product Segment -
Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External
Analgesics Markets Independently Analyzed with Annual Sales Figures in US$
Million for Years 1991 through 2000 (includes corresponding Graph/Chart) III-54

Table 90: Rest of Europe 15-Year Perspective for Analgesics by Product Segment -
Percentage Breakdown of Dollar Sales for Internal Analgesics (Aspirin,
Acetaminophen, Ibuprofen and Others) and External Analgesics Markets for 1998,
2008 & 2012 (includes corresponding Graph/Chart) III-55

5. Asia-Pacific III-56 A.Market Analysis III-56 Current and Future Analysis
III-56 The OTC Analgesic Market III-56 OTC Analgesics Market in Asia-Pacific
(2004): A Comparative Analysis of the Major Regions - Australia, China and South
Korea III-56 Aspirin - The Chinese Market III-56 Strategic Corporate
Developments III-57 B.Market Analytics III-58

Table 91: Asia-Pacific Recent Past, Current & Future Analysis for Analgesics by
Product Segment - Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and
Others) and External Analgesics Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2001 through 2010 (includes corresponding
Graph/Chart) III-58

Table 92: Asia-Pacific Long-term Projections for Analgesics by Product Segment -
Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External
Analgesics Markets Independently Analyzed with Annual Sales Figures in US$
Million for Years 2011 through 2015 (includes corresponding Graph/Chart) III-59

Table 93: Asia-Pacific Historic Review for Analgesics by Product Segment -
Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External
Analgesics Markets Independently Analyzed with Annual Sales Figures in US$
Million for Years 1991 through 2000 (includes corresponding Graph/Chart) III-59

Table 94: Asia-Pacific 15-Year Perspective for Analgesics by Product Segment -
Percentage Breakdown of Dollar Sales for Internal Analgesics (Aspirin,
Acetaminophen, Ibuprofen and Others) and External Analgesics Markets for 1998,
2008 & 2012 (includes corresponding Graph/Chart) III-60

6. Latin America III-61 A.Market Analysis III-61 Current and Future Analysis
III-61 B.Market Analytics III-61

Table 95: Latin American Recent Past, Current & Future Analysis for Analgesics
by Product Segment - Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and
Others) and External Analgesics Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2001 through 2010 (includes corresponding
Graph/Chart) III-61

Table 96: Latin American Long-term Projections for Analgesics by Product Segment
- Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and
External Analgesics Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
III-62

Table 97: Latin American Historic Review for Analgesics by Product Segment -
Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External
Analgesics Markets Independently Analyzed with Annual Sales Figures in US$
Million for Years 1991 through 2000 (includes corresponding Graph/Chart) III-62

Table 98: Latin American 15-Year Perspective for Analgesics by Product Segment -
Percentage Breakdown of Dollar Sales for Internal Analgesics (Aspirin,
Acetaminophen, Ibuprofen and Others) and External Analgesics Markets for 1998,
2008 & 2012 (includes corresponding Graph/Chart) III-63

7. Rest of World III-64 A.Market Analysis III-64 Current and Future Analysis
III-64 Strategic Corporate Developments III-64 B.Market Analytics III-64

Table 99: Rest of World Recent Past, Current & Future Analysis for Analgesics by
Product Segment - Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and
Others) and External Analgesics Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2001 through 2010 (includes corresponding
Graph/Chart) III-64

Table 100: Rest of World Long-term Projections for Analgesics by Product Segment
- Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and
External Analgesics Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
III-65

Table 101: Rest of World Historic Review for Analgesics by Product Segment -
Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others) and External
Analgesics Markets Independently Analyzed with Annual Sales Figures in US$
Million for Years 1991 through 2000 (includes corresponding Graph/Chart) III-65

Table 102: Rest of World 15-Year Perspective for Analgesics by Product Segment -
Percentage Breakdown of Dollar Sales for Internal Analgesics (Aspirin,
Acetaminophen, Ibuprofen and Others) and External Analgesics Markets for 1998,
2008 & 2012 (includes corresponding Graph/Chart) III-66

III-B. APPENDIX - POPULAR ANALGESIC BRANDS BY REGION

Canada III-67 France III-67 Germany III-68 United Kingdom III-69 Leading
Analgesics Brands for Children III-70 Italy III-70 Spain III-70 Rest of Europe
III-71 Asia-Pacific III-77 Latin America III-81

IV. COMPETITIVE LANDSCAPE

1. 3M Company (USA) 2. 999 Group (China) 3. Abbott Laboratories (USA) 4. Able
Laboratories, Inc. (USA) 5. Albemarle Corporation (USA) 6. Alembic Ltd. (India)
7. Aliachem Benelux BV (The Netherlands) 8. Alpharma US Pharmaceuticals (USA) 9.
Altana Pharma AG (Germany) 10. Anhui Xinli Pharmaceutical Co., Ltd. (China) 11.
Anshan Xianzhen Pharmaceutical Co., Ltd. (China) 12. Apoteket AB (Sweden) 13.
AstraZeneca PLC (UK) 14. Athenstaedt GmbH + Co. KG (Germany) 15. Atos
Pharmaceuticals & Medical Herbs (Egypt) 16. AWD Pharma GmbH and Co. KG (Dresden)
17. Bard Pharmaceuticals Ltd. (UK) 18. Barr Laboratories, Inc. (USA) 19. Bayer
AG (Germany) 20. Beijing Baoshutang Pharmaceutical Co., Ltd. (China) 21. Beijing
Shuangqiao Pharmaceutical Co. (China) 22. Beijing Shuguang Pharmaceutical Co.,
Ltd. (China) 23. Beijing United Pharmaceutical Co., Ltd. (China) 24. Beijing
Wanhui Pharmaceutical Group (China) 25. Beijing Zizhu Pharmaceutical Co., Ltd.
(China) 26. Belupo Doo (Croatia) 27. Berlin-Chemie AG (Germany) 28. Betapharm
Arzneimittel GmbH (Germany) 29. Biological E. Ltd. (India) 30. Biologische
Heilmittel Heel GmbH (Germany) 31. Boehringer Ingelheim GmbH (Germany) 32. Boots
Group PLC (The) (UK) 33. Bristol-Myers Squibb Co. (USA) 34. C P Pharmaceuticals
Ltd. (UK) 35. Cambrex Profarmaco Milano Srl (Italy) 36. Center Laboratories,
Inc. (Taiwan) 37. Central Pharmacal Co., Ltd. (The) (Taiwan) 38. Chang An
Chemical Ind Co., Ltd. (Taiwan) 39. Changchun Daxing Pharmaceutical Co., Ltd.
(China) 40. Chattem, Inc. (USA) 41. Chemferm Industrial Pharmaceuticals SA
(Spain) 42. Cheng Fong Chemical Co., Ltd. (Taiwan) 43. Chengdu Pharmaceutical
Corporation (China) 44. Chiesi Farmaceutici SpA (Italy) 45. Chifeng
Pharmaceutical Group Co., Ltd. (China) 46. Chongqing Daxin Pharmaceutical Co.,
Ltd. (China) 47. Chongqing Dikang Changjiang Pharmaceutical Co., Ltd. (China)
48. Clonmel Healthcare Ltd. (Ireland) 49. Clover Corporation Limited (Australia)
50. Codal Synto Ltd. (Cyprus) 51. Crookes Healthcare (UK) 52. Cullen & Davison
Ltd. (Ireland) 53. Daewoong Pharm Co., Ltd (Korea) 54. Del Laborat

To order this report:World Analgesics Market

http://www.reportlinker.com/p098419/World-Analgesics-Market.html

More market research reports here!

Reportlinker
Nicolas: nbo@reportlinker.com
US: (805)-652-2626
Intl: +1 805-652-2626

Copyright Business Wire 2009